Cannabis Freedom Index
← History

Medical 🇱🇹 Lithuania

Lithuania allows cannabis-based medicines

A law permitted doctors to prescribe registered medicines made from cannabis. Flower and home growing stayed illegal.[3][1]

Index score

1415

+1 point

The story

Lithuania’s medical reform, effective from May 2019, opened a route for registered cannabis-based medicines. Patients would receive pharmaceutical products whose safety and effectiveness had been demonstrated, under rules separate from the prohibition on recreational possession.[1][2]

A parliamentary route to medicines

Parliament approved the reform on 11 October 2018, with ninety members voting in favour and three abstaining.[1] Conservative politicians Mykolas Majauskas and Irena Degutienė had promoted the proposal, and the vote sent it to the president ahead of a planned 1 May start.[1]

Majauskas presented the change as a way for seriously ill patients to obtain medicines registered in the European Union, for treatment or symptom relief.[1] That placed the medicine and its authorisation at the centre of access: a diagnosis alone would not create an open market in cannabis.[1]

What the medicines register shows

The state register lists Epidyolex, a prescription oral solution containing cannabidiol at 100 mg per millilitre.[3] Its authorisation date is 19 September 2019, through the central European procedure.[3]

The register distinguishes being authorised from being supplied: one 100 ml bottle presentation is marked as supplied, while the three-bottle presentation is not.[3] It also marks this cannabidiol medicine as not controlled.[3] A patient’s actual route therefore depends on the particular product and package available through the medicines system.[3]

Manufacturers need separate permissions

The medicines agency provides a licensing route for manufacturing medicinal products containing Schedule I substances.[4] Applicants need both a pharmaceutical manufacturing licence and a licence for the controlled-substance activity.[4]

Those requirements regulate the businesses making medicines; they do not give individual patients a cultivation permit.[4] The agency’s licensing guidance keeps manufacturing, wholesale and other controlled activities within defined authorisations.[4]

Recreational reform followed another path

The drug-control department records that from January 2017, small unauthorised possession was handled as a criminal misdemeanour, replacing overlapping administrative and criminal liability.[2] The medical route developed alongside that criminal law.[1][2]

In April 2025, a parliamentary committee returned to the stalled proposal for administrative treatment of small cannabis possession.[5] Lithuania’s country profile tracks that debate separately from the registered-medicine route patients can use.[3][5]

Score by segment 0 to 10

  1. Possession · 25%1 1
  2. Personal cultivation · 25%2 2
  3. Punishment & enforcement · 20%2 2
  4. Sharing & gifting · 10%1 1
  5. Consumption · 10%1 1
  6. Legal access · 10%0 1+1

The bar shows the score after the change; the tick marks where it stood before. The scores after the change are Lithuania's current scores.

References

  1. LRT — Parliament approves cannabis medicines, 11 October 2018archived
  2. Lithuania Drug, Tobacco and Alcohol Control Department — National drug lawsarchived
  3. Lithuanian State Medicines Control Agency — Epidyolex registration and supplyarchived
  4. Lithuanian State Medicines Control Agency — Controlled-substance manufacturing licencesarchived
  5. BNS via Made in Vilnius — Committee revisits cannabis reform, 7 April 2025archived

Checked. The date and the event were compared with a source that was read. The score before the change is an editorial estimate.

    ↑↓ to move, ↵ to open.